CA2869257A1 - Methods for increasing cftr activity - Google Patents

Methods for increasing cftr activity Download PDF

Info

Publication number
CA2869257A1
CA2869257A1 CA2869257A CA2869257A CA2869257A1 CA 2869257 A1 CA2869257 A1 CA 2869257A1 CA 2869257 A CA2869257 A CA 2869257A CA 2869257 A CA2869257 A CA 2869257A CA 2869257 A1 CA2869257 A1 CA 2869257A1
Authority
CA
Canada
Prior art keywords
subject
cftr
depth
mucociliary clearance
free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2869257A
Other languages
English (en)
French (fr)
Inventor
Steven M. ROWE
Mark Dransfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of CA2869257A1 publication Critical patent/CA2869257A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2869257A 2012-04-06 2013-03-15 Methods for increasing cftr activity Abandoned CA2869257A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621043P 2012-04-06 2012-04-06
US61/621,043 2012-04-06
PCT/US2013/032268 WO2013151758A2 (en) 2012-04-06 2013-03-15 Methods for increasing cftr activity

Publications (1)

Publication Number Publication Date
CA2869257A1 true CA2869257A1 (en) 2013-10-10

Family

ID=49301152

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2869257A Abandoned CA2869257A1 (en) 2012-04-06 2013-03-15 Methods for increasing cftr activity

Country Status (8)

Country Link
US (2) US20150065539A1 (enExample)
EP (1) EP2833885A4 (enExample)
JP (1) JP6525203B2 (enExample)
CN (1) CN104619321A (enExample)
AU (2) AU2013243857A1 (enExample)
CA (1) CA2869257A1 (enExample)
HK (1) HK1206995A1 (enExample)
WO (1) WO2013151758A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690023A5 (de) * 1996-02-02 2000-03-31 Medichemie Ag Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut.
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
RS56894B1 (sr) 2008-08-13 2018-04-30 Vertex Pharma Farmaceutska kompozicija n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
RU2012114323A (ru) * 2009-09-12 2013-10-20 РЕКИТТ БЕНКИЗЕР ЭлЭлСи Применение гвайфенезина для ингибирования секреции муцина
KR101924162B1 (ko) * 2010-03-15 2018-11-30 버지니아 커먼웰스 유니버시티 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손
CN103180298A (zh) * 2010-03-19 2013-06-26 沃泰克斯药物股份有限公司 N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式
ME03652B (me) * 2011-05-18 2020-07-20 Vertex Pharmaceuticals Europe Ltd Deuterisani derivati ivakaftora

Also Published As

Publication number Publication date
JP6525203B2 (ja) 2019-06-05
WO2013151758A2 (en) 2013-10-10
AU2018200192B9 (en) 2019-07-25
AU2013243857A1 (en) 2014-10-16
US20150065539A1 (en) 2015-03-05
JP2015521157A (ja) 2015-07-27
AU2018200192A1 (en) 2018-02-01
US20170266177A1 (en) 2017-09-21
AU2018200192B2 (en) 2019-06-06
EP2833885A4 (en) 2015-12-16
HK1206995A1 (en) 2016-01-22
CN104619321A (zh) 2015-05-13
US10300052B2 (en) 2019-05-28
EP2833885A2 (en) 2015-02-11

Similar Documents

Publication Publication Date Title
JP6967111B2 (ja) プロスタサイクリン化合物、組成物およびその使用方法
Brand et al. Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis
RU2435585C2 (ru) Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких
US7524820B1 (en) Compounds of therapeutic value in the treatment of multiple sclerosis and other diseases wherein foamy cells are involved in the disease etiology
Ribeiro et al. Cystic fibrosis airway epithelial Ca2+ i signaling: the mechanism for the larger agonist-mediated Ca2+ i signals in human cystic fibrosis airway epithelia
EP2167040A1 (en) Intranasal carbetocin formulations and methods for the treatment of autism
Chai et al. Evaluation of co-delivery of colistin and ciprofloxacin in liposomes using an in vitro human lung epithelial cell model
JP2019523763A (ja) エラスターゼ阻害活性を有するベータヘアピンペプチド模倣体及びそのエアロゾル剤形
AU2018200192B9 (en) Methods for increasing CFTR activity
CA2584195A1 (fr) Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
Collins et al. Trofinetide. Glycine-proline-glutamate (GPE) analogue, treatment of Rett syndrome, treatment of fragile X syndrome
JP2017528417A (ja) 薬物送達強化剤
AU2006302591A1 (en) ApoE4 domain interaction inhibitors and methods of use thereof
EP3855180B1 (en) Method for evaluating pathology of cardiac failure
JP5283962B2 (ja) 医薬組成物
Blé et al. In vivo assessments of mucus dynamics in the rat lung using a Gd‐Cy5. 5‐bilabeled contrast agent for magnetic resonance and optical imaging
US9795653B2 (en) Use of inhalable powder formulation comprising growth hormone for preventing or treating NMDA receptor hypofunction-related diseases
Faude et al. R-(+)-verapamil, S-(-)-verapamil, and racemic verapamil inhibit human retinal pigment epithelial cell contraction
JP6108569B2 (ja) 虚血性疾患の治療又は予防のための薬剤及びその利用
Giorgetti Studies on the interaction between inhaled drug molecules and mucin
CN117599210A (zh) Phb2及其过表达试剂作为心肌细胞线粒体钙单向转运蛋白聚合体调控剂的应用
Alqahtani Development and application of in vitro approaches to assess the interactions of aerosolised drugs with pulmonary mucus
Bridges Pharmacology of AF508-CFTR Biosynthesis
Ribeiro et al. Cystic fibrosis airway epithelial Ca2+ i signaling: the 7
Acosta Advanced Design and Development of Novel Microparticulate/Nanoparticulate Dry Powder Inhalers for Targeted Treatment of Pulmonary Hypertension

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180314

FZDE Discontinued

Effective date: 20220803